British pharmaceutical giant GlaxoSmithKline (GSK) announced a strategic acquisition of biotech firm RAPT Therapeutics for $2.2 billion, securing the global rights to ozureprubart — a promising long-acting antibody therapy for food allergies. This innovative treatment, currently in Phase II clinical trials, could reshape how clinicians manage allergies to peanuts, milk, nuts, and more by offering dosing every 12 weeks rather than frequent injections.
Why It Matters:
• Represents a major industry pivot toward long-acting allergy biologics.
• Potential to challenge existing therapies (like omalizumab).
• Increases investor and clinical focus on respiratory & immunology portfolios.
👉 This acquisition signals a significant shift in allergy therapy development and highlights the accelerating pace of innovation in treating complex immunologic diseases.
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.